Citations (17)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Elena Galvani, Godefridus J Peters & Elisa Giovannetti. (2011) Thymidylate synthase inhibitors for non-small cell lung cancer. Expert Opinion on Investigational Drugs 20:10, pages 1343-1356.
Read now
Read now
Articles from other publishers (16)
Milan Jovanović, Katarina Nikolic, Marija Čarapić & Mara M. Aleksić. (2023) Electrochemical and theoretical study on interaction between erlotinib and DNA. Journal of Pharmaceutical and Biomedical Analysis 234, pages 115560.
Crossref
Crossref
Farag F. Sherbiny, Ashraf H. Bayoumi, Ahmed M. El-Morsy, Mohamed Sobhy & Mohamed Hagras. (2021) Design, Synthesis, biological Evaluation, and molecular docking studies of novel Pyrazolo[3,4-d]Pyrimidine derivative scaffolds as potent EGFR inhibitors and cell apoptosis inducers. Bioorganic Chemistry 116, pages 105325.
Crossref
Crossref
Hye Duck Choi & Min Jung Chang. (2020) Eye, hepatobiliary, and renal disorders of erlotinib in patients with non-small-cell lung cancer: A meta-analysis. PLOS ONE 15:7, pages e0234818.
Crossref
Crossref
Chihiro Endo-TsukudeJi-ichiro Sasaki, Sho Saeki, Norihiro Iwamoto, Megumi Inaba, Sunao Ushijima, Hiroto Kishi, Shinji Fujii, Hiroshi Semba, Kosuke Kashiwabara, Yukari Tsubata, Mitsuhiro Hayashi, Yuki Kai, Hideyuki Saito, Takeshi Isobe, Hirotsugu Kohrogi & Akinobu Hamada. (2018) Population Pharmacokinetics and Adverse Events of Erlotinib in Japanese Patients with Non-small-cell Lung Cancer: Impact of Genetic Polymorphisms in Metabolizing Enzymes and Transporters. Biological & Pharmaceutical Bulletin Biological and Pharmaceutical Bulletin 41:1, pages 47-56.
Crossref
Crossref
Didier Meulendijks, Wolfgang Jacob, Emile E. Voest, Morten Mau-Sorensen, Maria Martinez-Garcia, Alvaro Taus, Tania Fleitas, Andres Cervantes, Martijn P. Lolkema, Marlies H.G. Langenberg, Maja J. De Jonge, Stefan Sleijfer, Ji-Youn Han, Antonio Calles, Enriqueta Felip, Sang-We Kim, Jan H.M. Schellens, Sabine Wilson, Marlene Thomas, Maurizio Ceppi, Georgina Meneses-Lorente, Ian James, Suzana Vega-Harring, Rajiv Dua, Maitram Nguyen, Lori Steiner, Celine Adessi, Francesca Michielin, Birgit Bossenmaier, Martin Weisser & Ulrik N. Lassen. (2017) Phase Ib Study of Lumretuzumab Plus Cetuximab or Erlotinib in Solid Tumor Patients and Evaluation of HER3 and Heregulin as Potential Biomarkers of Clinical Activity. Clinical Cancer Research 23:18, pages 5406-5415.
Crossref
Crossref
SHANSHAN DING, FEI LONG & SHUJUAN JIANG. (2016) Acute myocardial infarction following erlotinib treatment for NSCLC: A case report. Oncology Letters 11:6, pages 4240-4244.
Crossref
Crossref
Fabienne Foufelle & Bernard Fromenty. (2016) Role of endoplasmic reticulum stress in drug‐induced toxicity. Pharmacology Research & Perspectives 4:1.
Crossref
Crossref
Kristen Kreamer & Debbie Riordan. (2015) Targeted Therapies for Non-Small Cell Lung Cancer: An Update on Epidermal Growth Factor Receptor and Anaplastic Lymphoma Kinase Inhibitors. Clinical Journal of Oncology Nursing 19:6, pages 734-742.
Crossref
Crossref
Lizza E.L. Hendriks, Janna Schoenmaekers, Jaap D. Zindler, Danielle B.P. Eekers, Ann Hoeben, Dirk K.M. De Ruysscher & Anne-Marie C. Dingemans. (2015) Safety of cranial radiotherapy concurrent with tyrosine kinase inhibitors in non-small cell lung cancer patients: A systematic review. Cancer Treatment Reviews 41:7, pages 634-645.
Crossref
Crossref
Elisa Giovannetti & Elena Galvani. 2015. Targeted Therapies for Solid Tumors. Targeted Therapies for Solid Tumors
9
29
.
Jukka M. Rintala, Johanna Savikko, Niina Palin, Sini E. Rintala, Petri K. Koskinen & Eva von Willebrand. (2014) Epidermal Growth Factor Inhibition, a Novel Pathway to Prevent Chronic Allograft Injury. Transplantation 98:8, pages 821-827.
Crossref
Crossref
Khaled Abdellatif, Eman Abdelall, Mohamed Abdelgawad, Rasha Ahmed & Rania Bakr. (2014) Synthesis and Anticancer Activity of Some New Pyrazolo[3,4-d]pyrimidin-4-one Derivatives. Molecules 19:3, pages 3297-3309.
Crossref
Crossref
Kimberly R. Doherty, Robert L. Wappel, Dominique R. Talbert, Patricia B. Trusk, Diarmuid M. Moran, James W. Kramer, Arthur M. Brown, Scott A. Shell & Sarah Bacus. (2013) Multi-parameter in vitro toxicity testing of crizotinib, sunitinib, erlotinib, and nilotinib in human cardiomyocytes. Toxicology and Applied Pharmacology 272:1, pages 245-255.
Crossref
Crossref
KOICHI KURISHIMA, HIROAKI SATOH, TAKAYUKI KABURAGI, YOSHIHIRO NISHIMURA, YOKO SHINOHARA, MASAHARU INAGAKI, TAKEO ENDO, TAKEFUMI SAITO, KENJI HAYASHIHARA, NOBUYUKI HIZAWA, HIROYUKI NAKAMURA, TAKESHI NAWA, KATSUNORI KAGOHASHI, KOJI KISHI, HIROICHI ISHIKAWA, HIDEO ICHIMURA, TOSHIO HASHIMOTO, YUKIO SATO, MITSUAKI SAKAI, KOICHI KAMIYAMA, TAKESHI MATSUMURA, KOJI UNOURA, TOSHIHIKO FUKUOKA, KEIKO UCHIUMI, AKIHIRO NOMURA & KINYA FURUKAWA. (2013) Erlotinib for elderly patients with non-small-cell lung cancer: Subset analysis from a population-based observational study by the Ibaraki Thoracic Integrative (POSITIVE) Research Group. Molecular and Clinical Oncology 1:5, pages 828-832.
Crossref
Crossref
Grace K. Dy, Jeffrey R. Infante, S. Gail Eckhardt, Silvia Novello, Wen Wee Ma, Suzanne F. Jones, Anne Huff, Qiong Wang, A. Benjamin Suttle, Lone H. Ottesen, Alex A. Adjei & Howard A. BurrisIIIIII. (2012) Phase Ib trial of the oral angiogenesis inhibitor pazopanib administered concurrently with erlotinib. Investigational New Drugs 31:4, pages 891-899.
Crossref
Crossref
Erzsébet Juhász, Joo-Hang Kim, Gaëlle Klingelschmitt & Stefan Walzer. (2013) Effects of erlotinib first-line maintenance therapy versus placebo on the health-related quality of life of patients with metastatic non-small-cell lung cancer. European Journal of Cancer 49:6, pages 1205-1215.
Crossref
Crossref